TREAT NL (TREatment of ATopic Eczema, the Netherlands) Registry

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The TREAT NL (TREatment of ATopic eczema, the Netherlands) registry is a national registry for children and adults with moderate-to-severe atopic eczema aiming to gather data on their prescribed photo- and systemic immunomodulating therapies. Atopic eczema is a common, chronic, itchy, inflammatory skin disease that can have a major impact on the quality of life of patients and their immediate surroundings. Serious atopic eczema patients are treated by means of photo- or systemic immunomodulating therapy. Of these mostly off-label applied therapies, there is insufficient evidence on the short and long term for their effectiveness, safety and cost-effectiveness. Moreover, good comparative research and real-life data are lacking. With the arrival of new expensive treatments it is crucial to get insight into these treatments in order to improve quality of care. By means of a prospective registry these data can be collected and help to obtain information for clinical practice, for answering research questions, for reducing costs and implementing the results by guidelines and decision aids.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Patient has a diagnosis of atopic eczema, based on the U.K. working party's diagnostic criteria;

• Starts with any type of phototherapy (e.g. UVB) or systemic immunomodulating therapy (e.g. cyclosporin, systemic glucocorticosteroids, azathioprine, methotrexate, mycophenolic acid, dupilumab);

• Has voluntarily signed and dated an informed consent prior to any study related procedure or has a legal representative to do so and is willing to comply with the requirements of this study protocol.

Locations
Other Locations
Netherlands
Department of Dermatology, Amsterdam University Medical Centres, University of Amsterdam, Research Institute Amsterdam Public Health and Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands
RECRUITING
Amsterdam
Contact Information
Primary
Angela L. Bosma
a.l.bosma@amsterdamumc.nl
+31205662757
Backup
Ariënna M. Hyseni
a.m.hyseni@amsterdamumc.nl
+31205662481
Time Frame
Start Date: 2017-11-01
Estimated Completion Date: 2027-10-31
Participants
Target number of participants: 500
Treatments
Patients with moderate-to-severe atopic eczema
Adult and pediatric patients that start treatment with phototherapy or systemic immunomodulating therapy for their atopic eczema
Authors
Priscella Eppenga
Related Therapeutic Areas
Sponsors
Leads: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

This content was sourced from clinicaltrials.gov